Category: Asean

Posted on

Blue California-FineCap™ Microencapsulation Platform Serves the Purpose

Rancho Santa Margarita, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) — Blue California, the producer of natural science-based ingredients, provides FineCap™ a comprehensive microencapsulation technology platform, equipped with 20 microencapsulation technologies, to deliver active ingredients and satisfy our clients’ needs.

Microencapsulation is the process in which tiny particles of solid, liquid, or gas are packaged within a matrix to form a capsule. The capsule is coated with a protective layer to avoid degradation from exposure to environmental factors such as water, oxygen, heat, and light.

“Brands that seek to expand their products’ qualities and boost their product portfolios will find many benefits to the FineCap platform,” said Dr. Cuie Yan, vice president of encapsulation. “FineCap takes microencapsulation a step further by offering a variety of technologies and targeting customers’ specific needs in tackling active ingredients with unique characteristics, such as strong odor, taste or stability problems that challenge formulators.”

Microencapsulation systems have been widely used across multiple industries, including the pharmaceutical, food, supplement, personal care, and fragrance industries, for active ingredients like medicines, nicotine, flavors/fragrances, polyunsaturated fatty acids, probiotics, natural pigments, vitamins, antioxidants, etc. Space agency NASA also uses encapsulation technologies for spacecraft. The pharmaceutical industry uses microencapsulation often to control the release of active pharma ingredients (API).
Blue California has created the FineCap platform to serve customers’ growing demands for better performance of API, functional ingredients, dietary supplements, flavors, fragrances, cosmetics, and personal care products.

 

For example, FineCap protects API from degradation, unpleasant tastes or aroma, and maintains its efficacy, by controlling its release. FineCap enables flavors to thrive in food and beverages with integrity, intensity, and extended shelf-life.

In fragrances, FineCap guarantees brands to control the precise fragrance release rate, location, and duration. Personal care products benefit from FineCap by protecting the delicate top-notes and cosmetic actives from oxygen, moisture, temperature, and light deterioration. A more comprehensive look into the benefits that FineCap delivers in these product segments can be found here.

“Our comprehensive FineCap platform has been serving and supporting formulators looking to launch market-winning products with better qualities and shelf-life that consumers are seeking,” said Dr. Yan. “We’re enabling brands to quickly create products from innovative concepts, benchtop development, to pilot and full commercial manufacturing, with improved efficacy, taste, color, texture, and shelf life, along with vegan, organic, Kosher, or Halal certificate.”

 

The FineCap platform investment builds on Blue California’s 25-year legacy of producing botanical extracts and now natural flavors and fragrances and focuses on developing sustainable ingredients made through bioconversion or fermentation.

###

About Blue California
Blue California is an entrepreneurial, science-based solutions provider and manufacturer of clean, natural, and sustainable ingredients used in food, beverage, flavor, fragrance, dietary supplements, personal care, and cosmetic products. For more than 25 years, Blue California has built a strong reputation for creating value in these diverse natural products and nature-inspired industries.

Attachment


Ana Arakelian
Blue California
+1-949-635-1991
ana@bluecal-ingredients.com
Posted on

ISW Holdings Inc. (ISWH) Reports Record Revenue, Forecasts $7M Per Month

NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) — via InvestorWire — ISW Holdings Inc. (OTC: ISWH) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.

To view the full publication and forward-looking statements, please visit: https://nnw.fm/YrdIL

Developments are translating to revenue and cash flow, resources that will underscore growth in 2022 and beyond with Pod City and other hosting and mining operations. During Q3, ISW Holdings Inc. (OTC: ISWH) reported revenue from operations of $1.075 million (including deferred revenues), up 2,435% on a year-over-year basis. That didn’t include a full three months of 550 new miners acquired from Minerset, 150 of which came as a result of ISWH meeting stock performance milestones. Total assets during Q3 increased 5,263% year to date to $9.56 million, while total liabilities decreased 73%, and total derivative liabilities decreased 98% to under $340,000. …

Looking ahead, revenue at Pod City will be comprised of hosting service fees, which aren’t contingent upon cryptocurrency pricing. Once running at full capacity, the company estimates annual revenue in excess of $7 million per month, a tremendous improvement compared to current capacity with the benefit of being recurring under service contracts.

About ISW Holdings

ISW Holdings, based in Nevada, is a diversified portfolio company comprised of essential business lines that serve consumer product demands. The company’s expertise lies in strategic brand development, early growth facilitation, as well as brand identity through its proprietary procurement process. Together, with its partners, ISW Holdings seeks to provide a structure that meets large scalability demands, as well as anticipated marketplace needs. The company is able to meet these needs through a variety of strategic innovative processes. ISWH is creating and managing brands across a spectrum of disruptive industries. It maneuvers its proprietary companies through critical stages of market development, which includes conceptualization, go-to-market strategies, engineering, product integration, and distribution efficiency. The company has also partnered with a well-known software development and consulting company, Bengala Technologies LLC, which is developing significant enhancements in the supply chain management space; and the partnership has a vitally needed patent now pending.

For more information about the company, visit www.ISWHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to ISWH are available in the company’s newsroom at http://ibn.fm/ISWH.

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only).
For more information please visit https://www.NetworkNewsWire.com.

Please see full terms of use and disclaimers on the NetworkNewsWire website, applicable to all content provided by NNW wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

 

Posted on

Why SNOMED CT? New platform presents a refreshed case for investing in the comprehensive clinical terminology

SNOMED International released today its refreshed SNOMED CT Case for Investment report.

London, United Kingdom, Dec. 16, 2021 (GLOBE NEWSWIRE) — SNOMED International released today its refreshed SNOMED CT Case for Investment report. Available on a new interactive platform, the Case for Investment presents evidence that SNOMED CT adds measurable value to a broad range of primary and secondary health processes leveraging SNOMED CT encoded data to enable improved patient outcomes. Through the narrative, the report provides accessible and understandable answers to questions such as, “what is SNOMED CT?”, ‘what makes SNOMED CT unique?’, “how and where is it in use globally?” and “why invest in SNOMED CT?”

SNOMED CT, the most comprehensive and multilingual clinical healthcare terminology in the world, possesses unique characteristics that differentiate it from other classifications and terminologies. Among these characteristics are SNOMED CT’s position as a core reference terminology, its clinically comprehensive 350,000+ concepts supported by a machine-readable semantic network, broad use and mandate in select countries.

Showcasing real world use and outcomes of SNOMED CT is the best way to demonstrate its value, understanding that SNOMED CT must be embedded in a clinical information system, health data & analytics platform or an interoperability solution for it to function. Through the Case for Investment, 10 examples of SNOMED CT use across data entry and integration, clinical information sharing, point of care analytics, population and management analytics and research domains have been featured. Ranging across different countries such as Australia, Canada, China, United Kingdom, United States, continued collection of additional SNOMED CT case studies remains an ongoing priority.

SNOMED International CEO, Don Sweete, commented on the development and outcomes of the Case for Investment. “There has been a tremendous evolution in SNOMED CT over the past 10 years and this report demonstrates the value that it offers healthcare systems and stakeholders worldwide” said Sweete. “With a complement of 41 Members that represent health systems globally, continuously refreshed knowledge and analysis on the nature, utility and value of standards like SNOMED CT can’t be overstated. Health system decision-makers need to be equipped with clear knowledge of how their investments in SNOMED CT translate into positive outcomes for the health of their nation’s citizens.”

In terms of conclusions, the report presents SNOMED CT as a scalable and “fit for purpose” clinical terminology, adhering to international criteria, data quality and suitability requirements. A part of the bigger picture, SNOMED CT is one of many contributing factors to improving patient outcomes, and studies show that the use of SNOMED CT-embedded systems can provide significant qualitative and quantitative patient outcome benefits.

Looking forward, SNOMED CT must also contemplate how it enables the future needs of medicine and research. A healthcare industry that is ever evolving, the future opportunities for SNOMED CT will be driven by new healthcare data sources and new healthcare technologies such as national cohorts, big data and AI, clinical genomics, phenomics and environment, etc.

Experience the breadth of the SNOMED CT Case for Investment through the organization’s interactive value platform at value.snomed.org.

Attachment

Kelly Kuru
SNOMED International
comms@snomed.org
Posted on

Blue California Expands Natural Flavor and Fragrance Portfolio with Production of Clean, Natural, and Sustainable Nerolidol

Rancho Santa Margarita, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) — Blue California announced the expansion of its natural flavor and fragrance portfolio of captive ingredients by producing a clean, sustainable nerolidol.

Nerolidol is a rare sesquiterpene alcohol ubiquitous in nature and found in many flowers and plants, particularly in Seville orange flower, also known as Neroli, which gives the aroma chemical its name.

It is recognized for its floral, woody aroma and can also be described as a fresh scent, blending well with citrus, apple, or rose but light enough to complement any type of scent or flavor. Nerolidol is therefore ideal for use in many applications and known for its relaxing effects.

Many brands looking to make products at a large scale using nerolidol find it to be cost-prohibitive and, for that reason, it hasn’t been widely used in modern-day product applications.

Yet, consumers seek clean-label fragrance products that are easy on the planet and fit into the clean and conscious fragrance and beauty movement. The Innova Beauty & Personal Care Survey 2020 notes that 51% of global consumers indicate that natural ingredients are very or extremely important to them when purchasing fragrances.

“Biotechnology is opening doors to sustainable ingredients that weren’t previously possible,” said Kathy Oglesby, head of flavors and fragrances at Blue California. “Our collaboration with innovation partner Conagen provides efficient and effective commercialization, leading us to deliver to our client-creators a full range of captive ingredients, trademarked Plantarôme,™ for use in our flavors and fragrances.”

Nerolidol is first in a full range of natural ingredients in the 2022 pipeline of Blue California’s Taste, Smell, and Beauty Division. Conagen develops one of the most high-yielding fermentation platforms for producing sesquiterpenes and lactones.

With its functional advantages in many industries due to its moderate polarity and optical activity, nerolidol is also a useful, sustainable fine chemical intermediate.

“Nerolidol is a foundational material with many uses in many markets. Plantarôme™ S is a sandalwood type material, and Plantarôme™ M, which is a natural musk, are both creating a lot of excitement in the marketplace,” said Oglesby.

Until now, synthetic musk was primarily used in the fragrance industry because traditional musk sources were wild plants, too rare to be useful, or wild animals, like musk deer and civet cats, too endangered to be ethical. Conagen and Blue California have teamed together to develop a modern, one-of-a-kind, natural, domestic plant-derived musk that is safe, versatile, and biodegradable.

“The launch of nerolidol is symbolic of the collaboration between Blue California and Conagen as we advance in the markets we can serve,” said Casey Lippmeier, Ph.D. vice president of innovation at Conagen. “Together, we are revolutionizing the flavor and fragrance ingredient industry with our disruptive capabilities for producing clean, sustainable solutions and product applications.”

About Blue California

Blue California is an entrepreneurial, science-based solutions provider and manufacturer of clean, natural, and sustainable ingredients used in food, beverage, flavor, fragrance, dietary supplements, personal care, and cosmetic products. For more than 25 years, Blue California has built a strong reputation for creating value in these diverse natural products and nature-inspired industries. www.bluecal-ingredients.com

About Conagen

Conagen is a product-focused, synthetic biology R&D company with large-scale manufacturing affiliates. Our scientists and engineers use the latest synthetic biology tools to develop high-quality, sustainable, nature-based products by precision fermentation and enzymatic bioconversion. We focus on the bioproduction of high-value ingredients for food, nutrition, flavors and fragrances, pharmaceutical, and renewable materials industries. www.conagen.com

Attachments

Ana Arakelian
Blue California
+1-949-635-1991
ana@bluecal-ingredients.com
Posted on

Nikkiso Clean Energy & Industrial Gases Group Becomes Ambassador Member of California Fuel Cell Partnership

TEMECULA, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) — Nikkiso Clean Energy & Industrial Gases Group (Group), a subsidiary of Nikkiso Co., Ltd (Japan), is proud to announce they have joined the California Fuel Cell Partnership (CaFCP) as an Ambassador.

The association is driving to establish 200 hydrogen fueling stations by 2025 for a sustainable future for zero emission cars, trucks and buses. Joining the CaFCP is part of the Group’s commitment to leading the change to a healthier world. Furthermore, the Group is expanding their global operations, opening a new engineering and service facility in Houston and Korea this year, and a new center in Germany in 2022.

“We are excited to be part of CaFCP to provide clean energy alternatives and look forward to collaborate with other CaFCP members in the fuel cell hydrogen fuel market,” according to Peter Wagner, CEO, Nikkiso Clean Energy & Industrial Gases Group.

There are several new hydrogen products under development, such as the first mobile Hydrogen refueler pumps, high capacity / high pressure reciprocating hydrogen pumps and containerized liquid hydrogen re-fueling stations. This is in addition to their ability to provide engineering, procurement, and full turnkey projects.

ABOUT CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (now a member of Nikkiso Co., Ltd.) member companies manufacture engineered cryogenic gas processing equipment and small-scale process plants for the liquefied natural gas (LNG), well services and industrial gas industries. Founded over 50 years ago, Cryogenic Industries is the parent company of ACD, Cosmodyne and Cryoquip and a commonly controlled group of approximately 20 operating entities.

For more information, please visit www.nikkisoCEIG.com and www.nikkiso.com.

MEDIA CONTACT:
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com

Posted on

Adagio Therapeutics Reports Reduction in In Vitro Neutralizing Activity of ADG20 Against Omicron SARS-CoV-2 Variant

Previously Reported In Vitro Data Demonstrating that Individual Omicron Mutations Were Not Associated with ADG20 Escape Do Not Translate to Omicron Authentic and Pseudovirus Assays

WALTHAM, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today provided an update following external in vitro analyses to evaluate neutralizing activity of ADG20 against the Omicron SARS-CoV-2 variant. The in vitro data generated through both authentic and pseudovirus testing of the Omicron variant show a greater than 300-fold reduction in neutralizing activity of ADG20 against Omicron. Additional analyses are ongoing, and the company plans to engage with regulatory and government agencies to assess the role ADG20 can play for the prevention and treatment of COVID-19, particularly as the industry’s understanding of the epidemiology and impact of Omicron and potential new variants develops.

“Due to the highly conserved and immunorecessive nature of the epitope recognized by ADG20, we anticipated that ADG20 would retain neutralizing activity against Omicron, consistent with activity observed in in vitro models with all other known variants of concern,” said Tillman Gerngross, Ph.D., chief executive officer of Adagio. “While the individual mutations present in the Omicron receptor binding domain were not associated with escape from ADG20 in the context of an original strain of the virus, new data show that the combination of mutations present in the Omicron spike protein led to a reduction in ADG20 neutralization that was not suggested by prior data. The continued prevalence of the Delta variant in the U.S. and other countries, evolution of SARS-CoV-2 variants and potential future coronaviruses means a multitude of therapies and approaches are needed. With an expert team committed to advancing antibody solutions that combat this unprecedented pandemic and a strong balance sheet, we’re conducting additional analyses to assess the optimal path forward with ADG20 as both a prophylactic and treatment option for COVID-19.”

ADG20 is an investigational monoclonal antibody (mAb) product candidate designed to provide broad and potent neutralizing activity against SARS-CoV-2, including variants of concern, for the prevention and treatment of COVID-19 with potential duration of protection for up to one year with a single injection. In previously disclosed in vitro studies, ADG20 retained activity against prior variants of concern including Alpha, Beta, Delta and Gamma. In addition, in vitro data demonstrated retained neutralizing activity of ADG20 against a diverse panel of circulating SARS-CoV-2 variants, including the Lambda, Mu and Delta plus variants. The safety and efficacy of ADG20 have not been established, and ADG20 is not authorized or approved for use in any country.

Adagio is currently evaluating ADG20 in global Phase 2/3 clinical trials for both the prevention and treatment of COVID-19. Based on the in vitro findings related to Omicron, Adagio plans to pause patient recruitment in its Phase 2/3 COVID-19 treatment trial at clinical sites in South Africa, where Omicron has emerged as the dominant variant. Adagio is evaluating next steps for its ADG20 program.

In vitro analyses were also conducted on ADG10, a second mAb in development, which showed minimal neutralizing activity against the Omicron variant in both authentic and pseudovirus neutralization assays.

About Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, including COVID-19 and influenza. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with the potential for a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple non-competing, broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers to support the completion of clinical trials and initial commercial launch, ensuring the potential for broad accessibility to people around the world. For more information, please visit www.adagiotx.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of ADG20, including the timing of future program updates and the initiation, modification and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; the additional and ongoing analyses to evaluate the activity of ADG20 against the Omicron variant and the potential of ADG20 to play a role as both a prophylactic and a treatment option for COVID-19; the risk/benefit profile of our product candidates to patients; and the adequacy of our cash, cash equivalents and marketable securities. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, the impacts of the COVID-19 pandemic on our business, clinical trials and financial position, unexpected safety or efficacy data observed during preclinical studies or clinical trials, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, and the uncertainties and timing of the regulatory approval process. Other factors that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in Adagio’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 and in Adagio’s future reports to be filed with the SEC. Such risks may be amplified by the impacts of the COVID-19 pandemic. Forward-looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.

Contacts:
Media Contact: Investor Contact:
Dan Budwick, 1AB Monique Allaire, THRUST Strategic Communications
Dan@1abmedia.com monique@thrustsc.com
Posted on

LeddarTech to Showcase Critical Sensing and Perception Solutions Enabling ADAS and Autonomous Driving at CES Las Vegas 2022

LeddarTech invites LiDAR manufacturers, Tier 1-2 suppliers, system integrators and automotive OEMs to discover the latest in ADAS and AD sensing and perception technologies at booth 7061 January 5-8 at CES

QUEBEC, Dec. 14, 2021 (GLOBE NEWSWIRE) — LeddarTech®, a global leader in providing the most flexible, robust and accurate ADAS and AD sensing technology, is pleased to announce its participation at five CES Las Vegas locations, January 5-8 ’22. The LeddarTech Showcase location will demonstrate four new leading solutions that enable OEMs, Tier 1-2 suppliers, system integrators and LiDAR manufacturers to solve critical ADAS and AD sensing and perception challenges across the entire value chain of the automotive, mobility and off-road vehicle markets. In addition, LeddarTech will also be present at four other Ecosystem Partner locations.

Introducing the LeddarTech Showcase (Booth #7061, LVCC West Hall)

The theme of LeddarTech’s CES destination booth (#7061) is “Solving Critical Sensing and Perception Challenges in ADAS and AD.” The booth, located in the all-new LVCC West Hall, in the heart of the Transportation/Vehicle Technology section, will feature groundbreaking technologies and solutions.

LeddarTech welcomes CES delegates to see firsthand solutions that address critical issues facing customers:

  1. Uncover the benefits of raw data fusion with LeddarVision™
    A comprehensive open sensor fusion and perception solution for automotive and off-road industrial vehicle ADAS and autonomous L2-L5 driving applications.
  2. Maximize LiDAR performance with LeddarSteer™ DBSD
    A scalable, adaptable and reliable solid-state, automotive-grade digital beam steering device (DBSD) for LiDAR manufacturers and vision system developers enhances range and resolution while optimizing costs and form factors.
  3. Explore a LiDAR development solution that reduces risk, costs and time, enabling faster time-to-market with the LiDAR XLRator™
    A versatile LiDAR development platform and auto-grade reference design solution. The XLRator is powered by the LeddarEngine (SoC and signal processing software) and critical components from development collaborators, ams OSRAM, STMicroelectronics and TE First Sensor that enable LiDAR manufacturers and Tier 1-2s and system integrators to develop automotive-grade LiDAR sensors meeting the specific requirements of OEMs. The XLRator platform also integrates the LeddarSteer DBSD.
  4. View the benefits of the LeddarEcho™ simulation tool in reducing development time
    A SiL sensor simulation software application for ADAS/AD system developers and integrators that models various sensor architectures and components to develop optimal LiDAR designs and validate the resulting performance within specific application use cases.

Also, visit LeddarTech at their Ecosystem Partner locations:

dSPACE (Booth #3555, LVCC West Hall), a company whose solutions have accelerated the development of innovative vehicle technology for decades, will host LeddarTech in demonstrating the LeddarEcho high-precision simulation tools and models created to support and significantly accelerate the development and validation of LeddarEngine-based LiDAR sensors and related ADAS & AD systems.

The Canadian Automotive Parts and Manufacturers’ Association (APMA) (Booth #6367, LVCC West Hall) is Canada’s national association representing OEM producers of parts, equipment, tools, supplies and advanced technology services for the worldwide automotive industry. LeddarTech is a proud member of the association and a technical contributor in the autonomous vehicle initiative “Project Arrow.”

Gouvernement du Québec – Investissement Québec (Booth #51827, The Venetian Expo, 2nd floor, 201 Sands Avenue, Las Vegas) is the go-to partner for international businesses thinking of locating to Québec. They also support the efforts made by Québec companies to access and expand into innovative markets. LeddarTech is proud to be a delegate on its CES trade mission. The company will be highlighting its sensor solutions for ITS and mobility applications.

Set a meeting with LeddarTech at CES:

LeddarTech will have representatives from all divisions available. You are invited to pre-arrange a meeting HERE for product demonstrations, media interviews, industry analyst or investor discussions, enquire about joining the Leddar™ Ecosystem or learn about the incredible career opportunities available. The team will be there to greet you at the booth or meet with you –by appointment only– in the LeddarTech business lounge #W318 at LVCC West Hall – Level 3.

About LeddarTech

LeddarTech provides the most flexible, robust and accurate sensing technology for advanced driver assistance systems (ADAS) and autonomous driving (AD). LeddarTech enables customers to solve critical environmental sensing, fusion and perception challenges across the entire value chain. The company offers cost-effective, scalable solutions such as LeddarVision™, a raw-data sensor fusion and perception platform that generates a comprehensive 3D environmental model with multi-sensor support for camera, radar and LiDAR configurations. LeddarTech supports LiDAR makers and Tier 1-2 automotive system integrators with LeddarSteer™, a digital beam steering device, and the LiDAR XLRator development solution for automotive-grade solid-state LiDAR based on the LeddarEngine™ and core components from global semiconductor partners. LeddarTech is responsible for several cutting-edge remote-sensing innovations, with over 100 patented technologies (granted or pending) enhancing ADAS and autonomous driving capabilities.

Additional information about LeddarTech is accessible at www.leddartech.com and on LinkedIn, Twitter, Facebook and YouTube.

Contact:
Daniel Aitken, Vice-President, Global Marketing, Communications and Product Management, LeddarTech Inc.
Tel.: + 1-418-653-9000 ext. 232
daniel.aitken@leddartech.com

Leddar, LeddarTech, LeddarSteer, LeddarEngine, LeddarVision, LeddarSP, LeddarCore, LeddarEcho, VAYADrive, VayaVision, XLRator and related logos are trademarks or registered trademarks of LeddarTech Inc. and its subsidiaries. All other brands, product names and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.

Posted on

Anaqua to Work with Lilium to Help Navigate Critical IP Management Processes

German aviation company to utilize Anaqua’s AQX platform to enhance innovation management, IP analytics, and stakeholder collaboration

Anaqua CEO Bob Romeo and Lilium Head of Intellectual Property Wulf Höflich at Lilium Headquarters

Bob Romeo, CEO of Anaqua, (left) with Wulf Höflich, Lilium’s Head of Intellectual Property – Engineering (right) at Lilium headquarters near Munich

BOSTON, Dec. 09, 2021 (GLOBE NEWSWIRE) — Anaqua, the leading provider of innovation and intellectual property management solutions, today announced that the Munich-based aviation company Lilium, positioned to be a global leader in sustainable regional air mobility, will use Anaqua’s AQX platform to help navigate its critical innovation and IP management processes.

Using the Lilium Jet, an all-electric vertical take-off and landing jet, offering industry leading payload, low noise and high performance with zero operating emissions, Lilium is creating a sustainable and accessible mode of high-speed, transportation for people and goods. Working with aerospace, technology and infrastructure leaders, commercial operations are projected to begin in 2024.

When selecting a system to meet its growing innovation and IP management needs, Lilium opted for Anaqua. Lilium will leverage Anaqua’s AQX software to enhance innovation management (from idea capture and assessment through to filing); IP analytics and Freedom to Operate (FTO) processes; docketing and reporting; and collaboration between the company, inventors, and outside counsel. AQX will deliver integrated patent analytics through Anaqua’s AcclaimIP solution, and provide a specialist trademark management module. Patent and trademark renewals will be managed through Anaqua Services.

Wulf Höflich, Lilium’s Head of Intellectual Property – Engineering said: “We were looking for a solutions provider who could work as an extension of our team to help manage our critical innovation and IP management processes. They needed to be able to provide excellent docketing and reporting tools, detailed IP analytics and FTO search capabilities, and enable seamless collaboration between our various stakeholders. And it all had to be implemented quickly. Anaqua were able to deliver on all these criteria.”

Commented Bob Romeo, CEO of Anaqua: “Lilium is a true leader in the highly innovative field of air mobility, and has an impressive range of unique, proprietary technology. We are excited to be working closely with Lilium, providing an integrated IP management system that will support and enhance their global innovation and operational excellence, and help protect their valuable IP assets.”

About Anaqua
Anaqua, Inc. is a premium provider of integrated intellectual property (IP) management technology solutions and services. Anaqua’s AQX platform combines best practice workflows with big data analytics and tech-enabled services to create an intelligent environment designed to inform IP strategy, enable IP decision-making, and streamline IP operations. Today, nearly half of the top 100 U.S. patent filers and global brands, as well as a growing number of law firms worldwide use Anaqua’s solutions. Over one million IP executives, attorneys, paralegals, administrators, and innovators use the platform for their IP management needs. The company’s global operations are headquartered in Boston, with offices across the U.S., Europe, and Asia. For additional information, please visit anaqua.com, or on LinkedIn.

Company Contact:
Amanda Hollis
Associate Director, Communications
Anaqua
617-375-2626
ahollis@Anaqua.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c41fcf52-c441-47a2-9031-44be15fa01e2